Fundraising FoxNovus Therapeutics
NASDAQ: ELDNIrvine, US · Delaware corporation
Find your way into Novus Therapeutics
Sign up to see every warm intro you have to Novus Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Novus Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Eledon Pharmaceuticals (formerly Novus Therapeutics) develops antibody-based therapies targeting the CD40 Ligand pathway for transplant organ protection and amyotrophic lateral sclerosis treatment, with tegoprubart as its lead clinical-stage candidate.
Founders & leadership
JK
Jon KuwaharaExecutive
GF
Gregory FlesherExecutive
SP
Steven PerrinPresident, Chief Scientific Officer, Director
DC
David-Alexandre C. GrosChief Executive Officer, Director
CC
Cheryl CohenNamed on SEC filing
KK
Keith KatkinNamed on SEC filing
JM
John McBrideNamed on SEC filing
GL
Gary LyonsNamed on SEC filing
CT
Catherine TurkelNamed on SEC filing
Board
EC
Erez ChimovitsBoard director
Reported raises · per SEC filings
Form D private placements$194.9M disclosed across 5 of 9 rounds · 1900–2024
▶$50MraisedMay 2024 · 24 investors · BiotechnologyRule 506(b)
▶$50MraisedMay 2024 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven PerrinExecutive Officer, Director
- David-Alexandre GrosExecutive Officer, Director
- June LeeDirector
- Allan KirkDirector
- John McBrideDirector
- James RobinsonDirector
- Keith KatkinDirector
- Jan HillsonDirector
- Paul LittleExecutive Officer
- Bryan SmithExecutive Officer
- Walter OgierDirector
- Amount sold
- $50M
- Sales commissions
- $1.6M
- Placement agents
- Leerink Partners LLC, Noble Capital Markets, Inc.
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35MraisedMay 2023 · 38 investors · BiotechnologyRule 506(b)
▶$35MraisedMay 2023 · 38 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jan HillsonDirector
- John McBrideDirector
- Bryan SmithExecutive Officer
- Keith KatkinDirector
- Walter OgierDirector
- Gary LyonsDirector
- Steven PerrinExecutive Officer, Director
- Paul LittleExecutive Officer
- June LeeDirector
- David-Alexandre GrosExecutive Officer, Director
- Amount sold
- $35M
- Sales commissions
- $1.2M
- Placement agents
- Noble Capital Markets, Inc., SVB Securities LLC
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$108.1MraisedSep 2020 · 35 investors · BiotechnologyRule 506(b)
▶$108.1MraisedSep 2020 · 35 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John McBrideDirector
- David-Alexandre GrosExecutive Officer, Director
- Steven N. PerrinDirector
- Gary LyonsDirector
- Jon KuwaharaExecutive Officer
- Keith A. KatkinDirector
- Walter OgierDirector
- Offering amount
- $108.1M
- Amount sold
- $108.1M
- Minimum investment
- $498
- Sales commissions
- $4.1M
- Placement agents
- Noble Capital Markets, Inc., SVB Leerink LLC
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$862.3KraisedJan 2020 · 10 investors · PharmaceuticalsRule 506(b)
▶$862.3KraisedJan 2020 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Keith KatkinDirector
- Gregory FlesherExecutive Officer, Director
- Erez ChimovitsDirector
- Cheryl CohenDirector
- Jon KuwaharaExecutive Officer
- John McBrideDirector
- Gary LyonsDirector
- Catherine TurkelExecutive Officer
- Offering amount
- $5.8M
- Amount sold
- $862.3K
- Sales commissions
- $60.4K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$862.3KraisedMay 2019 · 10 investors · PharmaceuticalsRule 506(b)
▶$862.3KraisedMay 2019 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jon KuwaharaExecutive Officer
- Gregory FlesherExecutive Officer, Director
- Erez ChimovitsDirector
- Cheryl CohenDirector
- Keith KatkinDirector
- John McBrideDirector
- Gary LyonsDirector
- Catherine TurkelExecutive Officer
- Offering amount
- $28.5M
- Amount sold
- $862.3K
- Sales commissions
- $60.4K
- Placement agents
- H.C. Wainwright and Co., LLC
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Novus Therapeutics do?
- Eledon Pharmaceuticals (formerly Novus Therapeutics) develops antibody-based therapies targeting the CD40 Ligand pathway for transplant organ protection and amyotrophic lateral sclerosis treatment, with tegoprubart as its lead clinical-stage candidate.
- How much funding has Novus Therapeutics raised?
- Novus Therapeutics has disclosed $194.9M raised across 5 of its 9 known rounds.
- Where is Novus Therapeutics headquartered?
- Novus Therapeutics is headquartered in Irvine, US.